 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Data presented at the Society of NeuroOncology (SNO) 28th Annual MeetingBerubicin currently being evaluated in an ongoing potentially pivotal study for the treatment of Glioblastoma Multiforme...

CNS Pharmaceuticals (NASDAQ: CNSP) Presents Updated Safety Data from Ongoing Potentially Pivotal Study Evaluating Berubicin in Advance of the Pre-Planned Interim Analysis of Efficacy

CNS Pharmaceuticals files to sell 3.76M shares of common stock for holders...

CNS Pharmaceuticals files to sell 3.76M shares of common stock for holders

HOUSTON, TX / ACCESSWIRE / November 16, 2023 / Glioblastoma is a highly aggressive type of brain cancer with no cure, leading to a grim prognosis and average survival time of only 14 to 16 months...

CNS Pharmaceuticals To Release Interim Data By The End Of The Year For Potential Glioblastoma Drug Candidate

- Enrollment numbers rise to 239 in ongoing potentially pivotal study of Berubicin for treatment of GBM; Expected full enrollment in December 2023- Topline data from preplanned interim analysis from...

CNS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Reiterates Company is on Track to Achieve Milestones for Berubicin Potentially Pivotal Study Before Year End

Live moderated webcast with John Climaco, Chief Executive Officer of CNS Pharmaceuticals on Tuesday, October 24th at 4:00 PM ETHOUSTON, TX / ACCESSWIRE / October 19, 2023 / CNS Pharmaceuticals, Inc...

CNS Pharmaceuticals to Participate at the Virtual Investor Ask the CEO Conference

- Live video webcast interactive Q&A with participating companies -FRENCHTOWN, NJ / ACCESSWIRE / October 18, 2023 / JTC Team ('JTC'), a fully integrated corporate communications and investor...

JTC Team Announces Presenting Company Line Up for the Virtual Investor Ask the CEO Conference Being Held October 24-25, 2023

HOUSTON, TX / ACCESSWIRE / October 16, 2023 / Glioblastoma is the most aggressive type of brain cancer, with an average survival of only 14 to 16 months after diagnosis. There is currently no cure...

Glioblastoma Is the Most Aggressive Type of Brain Cancer, With No Cure - CNS Pharmaceuticals Innovative Approach To Treatment Could Offer Hope

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

CNS Pharmaceuticals enrolls 229 of expected 243 patients in berubicin study

Company on track to achieve value-driving milestones before year-endHOUSTON, TX / ACCESSWIRE / October 11, 2023 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ('CNS' or the 'Company'), a biopharmaceutical...

CNS Pharmaceuticals' (NASDAQ:CNSP) Ongoing Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM) Continues Rapid Pace of Enrollment with 229 Patients Enrolled to Date

Live webcast presentation on Wednesday, September 13th at 10:30 AM ETHOUSTON, TX / ACCESSWIRE / September 5, 2023 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ('CNS' or the...

CNS Pharmaceuticals (NASDAQ: CNSP) to Present at the H.C. Wainwright 25th Annual Global Investment Conference

CNS Pharmaceuticals, Inc. is a preclinical stage pharmaceutical company, which engages in the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. Its product pipeline includes berubicin, and CNS-12. The company was founded by Waldemar Priebe in July 2017 and is headquartered in Houston, TX.

Watchers	4,905
52-Wk Low	$0.6105
52-Wk High	$4.40

Market Cap	$12.02M
Volume (M)	21,089.00
52-Wk High	$4.40
52-Wk Low	$0.6105

CNSP Cns Pharmaceuticals Inc

About

Feed

News

Sentiment

Fundamentals